UBS Group
DERM icon

UBS Group’s Journey Medical DERM Stock Holding History

UBS Group’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$591K Sell
83,514
-306,624
-79% -$1.75M ﹤0.01% 6122
2026
Q1 		$1.83M Buy
390,138
+99,912
+34% +$776K ﹤0.01% 5055
2025
Q4 		$2.24M Buy
290,226
+145,006
+100% +$1.14M ﹤0.01% 4869
2025
Q3 		$1.03M Sell
145,220
-13,531
-9% -$98.1K ﹤0.01% 5548
2025
Q2 		$1.14M Buy
158,751
+141,713
+832% +$979K ﹤0.01% 5333
2025
Q1 		$101K Sell
17,038
-5,325
-24% -$26.2K ﹤0.01% 7046
2024
Q4 		$87.4K Buy
+22,363
New +$122K ﹤0.01% 6962
2024
Q1 		– Sell
-13,376
Closed -$77K – 9429
2023
Q4 		$77K Buy
13,376
+11,921
+819% +$53.1K ﹤0.01% 6330
2023
Q3 		$3.99K Sell
1,455
-420
-22% -$938 ﹤0.01% 7496
2023
Q2 		$2.98K Sell
1,875
-2,323
-55% -$3.74K ﹤0.01% 7673
2023
Q1 		$6.59K Buy
+4,198
New +$7.83K ﹤0.01% 7906
2022
Q4 		– Sell
-1,444
Closed -$4K – 10782
2022
Q3 		$4K Sell
1,444
-1,245
-46% -$4.24K ﹤0.01% 9347
2022
Q2 		$10K Sell
2,689
-485
-15% -$1.92K ﹤0.01% 7950
2022
Q1 		$15K Sell
3,174
-74
-2% -$369 ﹤0.01% 7821
2021
Q4 		$17K Buy
+3,248
New +$23.5K ﹤0.01% 8052

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group's DERM Position: Q2 2026 in Review

UBS Group reduced its Journey Medical (DERM) stake by 79% in Q2 2026, selling an estimated $1.75M and leaving 83,514 shares worth $591K. The position accounts for ﹤0.01% of the portfolio, ranked #6122.

UBS Group first reported a position in DERM in Q4 2021 and has held it in 15 quarters since. The position peaked at $2.24M in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • UBS Group held 83,514 shares of Journey Medical worth $591K as of Q2 2026.
  • UBS Group sold 306,624 Journey Medical shares in Q2 2026, an estimated $1.75M.
  • Journey Medical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6122 holding.
  • UBS Group first reported a position in Journey Medical in Q4 2021 and has held it in 15 quarters since.
  • UBS Group's Journey Medical position peaked at $2.24M in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.